Acrivon Therapeutics Inc (nasdaq:ACRV) Share Price

Company Profile

Business description
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Contact
480 Arsenal Way
Suite 100
WatertownMA02472
USA
T: +1 617 207-8979
https://www.acrivon.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
76

Recommended

Discounted exit raises investor concerns.

Yingqi Tan, CFA | 21 September 2026

The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.

Jacob Robbins | 21 September 2026

Morningstar analysts’ take on the takeover for this undervalued industrial player.

Esther Holloway | 20 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,951.00	31.90	0.36%
CAC 40	8,157.65	18.71	0.23%
DAX 40	25,600.01	25.00	0.10%
Dow JONES (US)	51,735.76	313.07	-0.60%
FTSE 100	10,723.24	15.77	-0.15%
HKSE	25,087.75	45.04	0.18%
NASDAQ	27,210.56	88.47	0.33%
Nikkei 225	65,018.95	882.70	1.38%
NZX 50 Index	13,875.48	54.28	0.39%
S&P 500	7,760.15	4.55	-0.06%
S&P/ASX 200	8,757.80	25.90	0.30%
SSE Composite Index	3,952.13	2.22	0.06%